Flow cytometry analysis of the tumor microenvironment showed a significant increase in the proportion of CD8 T cells specific to the tumor-associated retrovirus antigen, envelope glycoprotein gp70, following combination viroimmunotherapy compared to monotherapies with T-VEC or trabectedin. Here, CD8A is linked to neoplasm.